Receipt date: 06/17/2011

OK TO ENTER: /SH/
06/20/2011

Docket No. PAT100-8024-US-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
Sedrani et al.
APPLICATION NO: 09/585,743
FILED: June 2, 2000
FOR: Rapamycin Assay

Art Unit: 1641
Examiner: HAQ, SHAFIQUL
Confirmation No. 7135

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Dear Sir:

By this paper, Applicants wish to amend the specification of the above referenced application as follows:

Amendments to the specification are given on page 2 of this paper; and
Remarks/Arguments begin on page 3 of this paper.

Amendments to the specification

Please add the following new paragraph on page 13, line 5 (before Example 1)

Brief Description of the Drawings

Fig 1 is a line graph depicting titer curves for mouse (M1) and mouse (M7).

Fig. 2 is a line graph depicting a standard curve for monoclonal antibody M7-91.

Fig. 3 is a bar graph showing a comparison of binding levels of 17 selected monoclonal antibodies in the rapamycin-BSA and FK-506 assays.

Fig. 4 is a bar graph showing a comparison of cross reactivity of 17 selected monoclonal antibodies in the rapamycin-BSA and FK-506 assays.

Fig. 5 is a line graph showing an inhibition curve for binding of the M7-91 antibody (M7.91.13) to BSA-rapamycin in the presence of different concentrations of free rapamycin.

Fig. 6A-B are line graphs showing a competitive assay comparing the M7-91 antibody (M7.91.13) with M1-303 (M1.303.3) antibody.

Figs. 7A-C are bar graphs of hybridoma B3-203 binding selectively to 40-O-(2-hydroxyethyl)-rapamycin-B- SA (7A), of hybridoma B3-113 binding both 40-O-(2-hydroxyethyl)-rapamycin-BSA and rapamycin-BSA conjugated through position 28 (7B), of hybridoma B3-164 binding rapamycin coupled to BSA through position 40 (7C).

Figs. 8A-C are line graphs showing antibodies produced by hybridoma B3-203 react strongly with 40-O-(2-hydroxyethyl)-rapamycin with low crossreactivity for rapamycin (FIG. 8A) and antibodies produced by hybridoma B3-113 and B3-164 bind equally well to 40-O-(2-hydroxyethyl)-rapamycin and rapamycin (FIGS. 8B and 8C).

REMARKS

Applicants would like to thank Examiner Haq for discussing the present case with Applicants on June 15, 2011. Applicants have amended the specification to include a "Brief Description of the Drawings". Support for this amendment can be found on page 18, lines 19-23 and page 20, line 1 through page 21, line 26.

Applicants also submit herewith a new supplemental IDS, which consideration is kindly requested.

CONCLUSION

The Commissioner is authorized to charge Deposit Account No. 19-0134 for the $180.00 fee for submitting the IDS. Applicants believe that no other fees are due. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936

/Christine McCormack/

Christine McCormack
Attorney for Applicant
Reg. No. 61,331
(617) 871-8486

Date: June 17, 2011